Well-differentiated neurocytoma: What is the best available treatment?

Dirk Rades, Fabian Fehlauer, Katrin Lamszus, Steven E. Schild, Christian Hagel, Manfred Westphal, Winfried Alberti

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Most neurocytomas are well differentiated, being associated with better long-term survival than the more aggressive atypical lesions. Atypical neurocytomas are characterized by an MIB-1 labeling index >3% or atypical histologic features. This analysis focuses on well-differentiated neurocytomas in order to define the optimal treatment. A case with a follow-up of 132 months is presented. The patient developed two recurrences two and four years after first surgery, each showing an increasing proliferation activity. Furthermore, all published well-differentiated neurocytoma cases were reviewed for surgery, radiotherapy, and prognosis. Additional relevant data were obtained from the authors. Complete resection (CTR), complete resection plus radiotherapy (CTR + RT), incomplete resection (ITR), and incomplete resection plus radiotherapy (ITR + RT) were compared for outcome by using the Kaplan-Meier method and the log-rank test. Data were complete in 301 patients (CTR, 108; CTR + RT, 27; ITR, 81; ITR + RT, 85). Local control and survival were better after CTR than after ITR (P < 0.0001 and P = 0.0085, respectively). Radiotherapy improved local control after ITR (P < 0.0001) and after CTR (P = 0.0474), but not survival (P = 0.17 and P = 1.0, respectively). In the ITR + RT group, doses ≤54 Gy (n = 33) and >54 Gy (n = 32) were not significantly different for local control (P = 0.88) and survival (P = 0.95). The data demonstrated CTR to be superior to ITR for local control and survival. After CTR and ITR, radiotherapy improved local control, but not survival. A radiation dose of 54 Gy appeared sufficient. Application of postoperative radiotherapy should be decided individually, taking into account the risk of local failure, the need for another craniotomy, and potential radiation toxicity.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalNeuro-Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Neurocytoma
Radiotherapy
Survival
Radiation
Therapeutics
Craniotomy
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Rades, D., Fehlauer, F., Lamszus, K., Schild, S. E., Hagel, C., Westphal, M., & Alberti, W. (2005). Well-differentiated neurocytoma: What is the best available treatment? Neuro-Oncology, 7(1), 77-83. https://doi.org/10.1215/S1152851704000584

Well-differentiated neurocytoma : What is the best available treatment? / Rades, Dirk; Fehlauer, Fabian; Lamszus, Katrin; Schild, Steven E.; Hagel, Christian; Westphal, Manfred; Alberti, Winfried.

In: Neuro-Oncology, Vol. 7, No. 1, 01.2005, p. 77-83.

Research output: Contribution to journalArticle

Rades, D, Fehlauer, F, Lamszus, K, Schild, SE, Hagel, C, Westphal, M & Alberti, W 2005, 'Well-differentiated neurocytoma: What is the best available treatment?', Neuro-Oncology, vol. 7, no. 1, pp. 77-83. https://doi.org/10.1215/S1152851704000584
Rades D, Fehlauer F, Lamszus K, Schild SE, Hagel C, Westphal M et al. Well-differentiated neurocytoma: What is the best available treatment? Neuro-Oncology. 2005 Jan;7(1):77-83. https://doi.org/10.1215/S1152851704000584
Rades, Dirk ; Fehlauer, Fabian ; Lamszus, Katrin ; Schild, Steven E. ; Hagel, Christian ; Westphal, Manfred ; Alberti, Winfried. / Well-differentiated neurocytoma : What is the best available treatment?. In: Neuro-Oncology. 2005 ; Vol. 7, No. 1. pp. 77-83.
@article{89e4859f341e412285d5634266449a21,
title = "Well-differentiated neurocytoma: What is the best available treatment?",
abstract = "Most neurocytomas are well differentiated, being associated with better long-term survival than the more aggressive atypical lesions. Atypical neurocytomas are characterized by an MIB-1 labeling index >3{\%} or atypical histologic features. This analysis focuses on well-differentiated neurocytomas in order to define the optimal treatment. A case with a follow-up of 132 months is presented. The patient developed two recurrences two and four years after first surgery, each showing an increasing proliferation activity. Furthermore, all published well-differentiated neurocytoma cases were reviewed for surgery, radiotherapy, and prognosis. Additional relevant data were obtained from the authors. Complete resection (CTR), complete resection plus radiotherapy (CTR + RT), incomplete resection (ITR), and incomplete resection plus radiotherapy (ITR + RT) were compared for outcome by using the Kaplan-Meier method and the log-rank test. Data were complete in 301 patients (CTR, 108; CTR + RT, 27; ITR, 81; ITR + RT, 85). Local control and survival were better after CTR than after ITR (P < 0.0001 and P = 0.0085, respectively). Radiotherapy improved local control after ITR (P < 0.0001) and after CTR (P = 0.0474), but not survival (P = 0.17 and P = 1.0, respectively). In the ITR + RT group, doses ≤54 Gy (n = 33) and >54 Gy (n = 32) were not significantly different for local control (P = 0.88) and survival (P = 0.95). The data demonstrated CTR to be superior to ITR for local control and survival. After CTR and ITR, radiotherapy improved local control, but not survival. A radiation dose of 54 Gy appeared sufficient. Application of postoperative radiotherapy should be decided individually, taking into account the risk of local failure, the need for another craniotomy, and potential radiation toxicity.",
author = "Dirk Rades and Fabian Fehlauer and Katrin Lamszus and Schild, {Steven E.} and Christian Hagel and Manfred Westphal and Winfried Alberti",
year = "2005",
month = "1",
doi = "10.1215/S1152851704000584",
language = "English (US)",
volume = "7",
pages = "77--83",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Well-differentiated neurocytoma

T2 - What is the best available treatment?

AU - Rades, Dirk

AU - Fehlauer, Fabian

AU - Lamszus, Katrin

AU - Schild, Steven E.

AU - Hagel, Christian

AU - Westphal, Manfred

AU - Alberti, Winfried

PY - 2005/1

Y1 - 2005/1

N2 - Most neurocytomas are well differentiated, being associated with better long-term survival than the more aggressive atypical lesions. Atypical neurocytomas are characterized by an MIB-1 labeling index >3% or atypical histologic features. This analysis focuses on well-differentiated neurocytomas in order to define the optimal treatment. A case with a follow-up of 132 months is presented. The patient developed two recurrences two and four years after first surgery, each showing an increasing proliferation activity. Furthermore, all published well-differentiated neurocytoma cases were reviewed for surgery, radiotherapy, and prognosis. Additional relevant data were obtained from the authors. Complete resection (CTR), complete resection plus radiotherapy (CTR + RT), incomplete resection (ITR), and incomplete resection plus radiotherapy (ITR + RT) were compared for outcome by using the Kaplan-Meier method and the log-rank test. Data were complete in 301 patients (CTR, 108; CTR + RT, 27; ITR, 81; ITR + RT, 85). Local control and survival were better after CTR than after ITR (P < 0.0001 and P = 0.0085, respectively). Radiotherapy improved local control after ITR (P < 0.0001) and after CTR (P = 0.0474), but not survival (P = 0.17 and P = 1.0, respectively). In the ITR + RT group, doses ≤54 Gy (n = 33) and >54 Gy (n = 32) were not significantly different for local control (P = 0.88) and survival (P = 0.95). The data demonstrated CTR to be superior to ITR for local control and survival. After CTR and ITR, radiotherapy improved local control, but not survival. A radiation dose of 54 Gy appeared sufficient. Application of postoperative radiotherapy should be decided individually, taking into account the risk of local failure, the need for another craniotomy, and potential radiation toxicity.

AB - Most neurocytomas are well differentiated, being associated with better long-term survival than the more aggressive atypical lesions. Atypical neurocytomas are characterized by an MIB-1 labeling index >3% or atypical histologic features. This analysis focuses on well-differentiated neurocytomas in order to define the optimal treatment. A case with a follow-up of 132 months is presented. The patient developed two recurrences two and four years after first surgery, each showing an increasing proliferation activity. Furthermore, all published well-differentiated neurocytoma cases were reviewed for surgery, radiotherapy, and prognosis. Additional relevant data were obtained from the authors. Complete resection (CTR), complete resection plus radiotherapy (CTR + RT), incomplete resection (ITR), and incomplete resection plus radiotherapy (ITR + RT) were compared for outcome by using the Kaplan-Meier method and the log-rank test. Data were complete in 301 patients (CTR, 108; CTR + RT, 27; ITR, 81; ITR + RT, 85). Local control and survival were better after CTR than after ITR (P < 0.0001 and P = 0.0085, respectively). Radiotherapy improved local control after ITR (P < 0.0001) and after CTR (P = 0.0474), but not survival (P = 0.17 and P = 1.0, respectively). In the ITR + RT group, doses ≤54 Gy (n = 33) and >54 Gy (n = 32) were not significantly different for local control (P = 0.88) and survival (P = 0.95). The data demonstrated CTR to be superior to ITR for local control and survival. After CTR and ITR, radiotherapy improved local control, but not survival. A radiation dose of 54 Gy appeared sufficient. Application of postoperative radiotherapy should be decided individually, taking into account the risk of local failure, the need for another craniotomy, and potential radiation toxicity.

UR - http://www.scopus.com/inward/record.url?scp=14644401705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644401705&partnerID=8YFLogxK

U2 - 10.1215/S1152851704000584

DO - 10.1215/S1152851704000584

M3 - Article

C2 - 15701284

AN - SCOPUS:14644401705

VL - 7

SP - 77

EP - 83

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -